Diffusion Pharmaceuticals Inc. (DFFN) |
| 4.4 0.41 (10.28%) 08-16 16:00 |
| Open: | 4.23 |
| High: | 5.19 |
| Low: | 4.165 |
| Volume: | 349,445 |
| Market Cap: | 9(M) |
| PE Ratio: | -0.62 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 14.37 |
| 52w Low: | 4.139999 |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 15 Jul 2025
Tract Bio adds CMO and board members as stem cell pipeline advances - The Pharma Letter
Thu, 08 Feb 2024
Vertex co-founder Josh Boger joins Boston biotech working on dementia drug - The Business Journals
Tue, 15 Aug 2023
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma - Yahoo Finance
Thu, 30 Mar 2023
EIP Pharma and Diffusion Pharmaceuticals Announce Merger - GlobeNewswire
Sun, 24 Apr 2022
U.S stock market gainers for the week - Nairametrics
Mon, 18 Apr 2022
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split - citybiz
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
